• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

    12/9/21 10:27:20 AM ET
    $ABBV
    $ALL
    $ALSN
    $AMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Property-Casualty Insurers
    Finance
    Get the next $ABBV alert in real time by email

    Upgrades

    According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

    BMO Capital upgraded the previous rating for Nuvei Corp (NASDAQ:NVEI) from Market Perform to Outperform.

    For Cadence Bank (NYSE:CADE), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. Cadence Bank earned $0.67 in the third quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.12 and a 52-week-low of $14.47. Cadence Bank closed at $29.39 at the end of the last trading period.

    According to Raymond James, the prior rating for Boyd Gaming Corp (NYSE:BYD) was changed from Outperform to Strong Buy. For the third quarter, Boyd Gaming had an EPS of $1.30, compared to year-ago quarter EPS of $0.38. The current stock performance of Boyd Gaming shows a 52-week-high of $71.00 and a 52-week-low of $40.44. Moreover, at the end of the last trading period, the closing price was at $64.48.

    Wells Fargo upgraded the previous rating for LGI Homes Inc (NASDAQ:LGIH) from Underweight to Equal-Weight. In the third quarter, LGI Homes showed an EPS of $4.05, compared to $2.45 from the year-ago quarter. The current stock performance of LGI Homes shows a 52-week-high of $188.00 and a 52-week-low of $95.54. Moreover, at the end of the last trading period, the closing price was at $155.99.

    For Twilio Inc (NYSE:TWLO), Barclays upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Twilio showed an EPS of $0.01, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $457.30 and a 52-week-low of $235.00. Twilio closed at $274.81 at the end of the last trading period.

    Stifel upgraded the previous rating for JFrog Ltd (NASDAQ:FROG) from Hold to Buy. JFrog earned $0.01 in the third quarter, compared to $0.05 in the year-ago quarter. At the moment, the stock has a 52-week-high of $72.28 and a 52-week-low of $27.65. JFrog closed at $32.37 at the end of the last trading period.

    Oppenheimer upgraded the previous rating for Sarepta Therapeutics Inc (NASDAQ:SRPT) from Perform to Outperform. For the third quarter, Sarepta Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $1.42. The stock has a 52-week-high of $181.83 and a 52-week-low of $65.30. At the end of the last trading period, Sarepta Therapeutics closed at $86.02.

    For Engagesmart Inc (NYSE:ESMT), Citigroup upgraded the previous rating of Neutral to Buy. In the third quarter, Engagesmart showed an EPS of $0.06, compared to $0.00 from the year-ago quarter.

    Credit Suisse upgraded the previous rating for CVR Energy Inc (NYSE:CVI) from Underperform to Neutral. CVR Energy earned $0.24 in the third quarter, compared to $0.57 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.02 and a 52-week-low of $11.22. CVR Energy closed at $16.50 at the end of the last trading period.

    For UiPath Inc (NYSE:PATH), Berenberg upgraded the previous rating of Hold to Buy. UiPath earned $0.00 in the third quarter, compared to $0.41 in the year-ago quarter. The current stock performance of UiPath shows a 52-week-high of $90.00 and a 52-week-low of $42.02. Moreover, at the end of the last trading period, the closing price was at $47.71.

    Wolfe Research upgraded the previous rating for Linde PLC (NYSE:LIN) from Peer Perform to Outperform. In the third quarter, Linde showed an EPS of $2.73, compared to $2.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $340.16 and a 52-week-low of $240.80. Linde closed at $333.19 at the end of the last trading period.

    Needham upgraded the previous rating for Inogen Inc (NASDAQ:INGN) from Hold to Buy. In the third quarter, Inogen showed an EPS of $0.53, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $82.35 and a 52-week-low of $29.28. At the end of the last trading period, Inogen closed at $33.08.

    For Instructure Holdings Inc (NYSE:INST), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. For the third quarter, Instructure Holdings had an EPS of $0.24, compared to year-ago quarter EPS of $0.13.

    Morgan Stanley upgraded the previous rating for United Rentals Inc (NYSE:URI) from Underweight to Equal-Weight. In the third quarter, United Rentals showed an EPS of $6.58, compared to $5.40 from the year-ago quarter. The current stock performance of United Rentals shows a 52-week-high of $414.99 and a 52-week-low of $217.39. Moreover, at the end of the last trading period, the closing price was at $356.96.

    Barclays upgraded the previous rating for CRH PLC (NYSE:CRH) from Underweight to Equal-Weight. The current stock performance of CRH shows a 52-week-high of $53.99 and a 52-week-low of $39.10. Moreover, at the end of the last trading period, the closing price was at $50.94.

    Atlantic Equities upgraded the previous rating for Yum Brands Inc (NYSE:YUM) from Neutral to Overweight. For the third quarter, Yum Brands had an EPS of $1.22, compared to year-ago quarter EPS of $1.01. At the moment, the stock has a 52-week-high of $135.77 and a 52-week-low of $101.18. Yum Brands closed at $131.74 at the end of the last trading period.

    According to JP Morgan, the prior rating for Brookfield Renewable Partners LP (NYSE:BEP) was changed from Neutral to Overweight. Brookfield Renewable earned $0.21 in the third quarter, compared to $0.44 in the year-ago quarter. The stock has a 52-week-high of $88.41 and a 52-week-low of $33.56. At the end of the last trading period, Brookfield Renewable closed at $34.38.

    According to JP Morgan, the prior rating for Brookfield Renewable Corp (NYSE:BEPC) was changed from Neutral to Overweight. At the moment, the stock has a 52-week-high of $107.83 and a 52-week-low of $34.13. Brookfield Renewable closed at $34.90 at the end of the last trading period.

    For Occidental Petroleum Corp (NYSE:OXY), JP Morgan upgraded the previous rating of Underweight to Neutral. Occidental Petroleum earned $0.87 in the third quarter, compared to $0.84 in the year-ago quarter. The current stock performance of Occidental Petroleum shows a 52-week-high of $35.75 and a 52-week-low of $16.88. Moreover, at the end of the last trading period, the closing price was at $30.77.

    Morgan Stanley upgraded the previous rating for Rio Tinto PLC (NYSE:RIO) from Equal-Weight to Overweight. The current stock performance of Rio Tinto shows a 52-week-high of $95.97 and a 52-week-low of $59.58. Moreover, at the end of the last trading period, the closing price was at $63.88.

    JP Morgan upgraded the previous rating for Phillips 66 (NYSE:PSX) from Neutral to Overweight. For the third quarter, Phillips 66 had an EPS of $3.18, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $94.34 and a 52-week-low of $63.19. At the end of the last trading period, Phillips 66 closed at $71.85.

    See all analyst ratings upgrades.

    Downgrades

    According to Goldman Sachs, the prior rating for Reata Pharmaceuticals Inc (NASDAQ:RETA) was changed from Buy to Neutral. Reata Pharmaceuticals earned $1.27 in the third quarter, compared to $1.31 in the year-ago quarter. At the moment, the stock has a 52-week-high of $153.41 and a 52-week-low of $32.00. Reata Pharmaceuticals closed at $54.42 at the end of the last trading period.

    According to RBC Capital, the prior rating for Diageo PLC (NYSE:DEO) was changed from Sector Perform to Underperform. At the moment, the stock has a 52-week-high of $213.12 and a 52-week-low of $153.67. Diageo closed at $211.93 at the end of the last trading period.

    According to Jefferies, the prior rating for Southwest Airlines Co (NYSE:LUV) was changed from Buy to Hold. In the third quarter, Southwest Airlines showed an EPS of $0.23, compared to $1.99 from the year-ago quarter. The stock has a 52-week-high of $64.75 and a 52-week-low of $42.39. At the end of the last trading period, Southwest Airlines closed at $45.27.

    For Snap One Holdings Corp (NASDAQ:SNPO), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. In the third quarter, Snap One Holdings showed an EPS of $0.24, compared to $0.02 from the year-ago quarter.

    Morgan Stanley downgraded the previous rating for Liberty SiriusXM Group (NASDAQ:LSXMA) from Overweight to Equal-Weight. The current stock performance of Liberty SiriusXM Gr shows a 52-week-high of $56.26 and a 52-week-low of $39.40. Moreover, at the end of the last trading period, the closing price was at $48.46.

    SVB Leerink downgraded the previous rating for Reata Pharmaceuticals Inc (NASDAQ:RETA) from Outperform to Market Perform. For the third quarter, Reata Pharmaceuticals had an EPS of $1.27, compared to year-ago quarter EPS of $1.31. The current stock performance of Reata Pharmaceuticals shows a 52-week-high of $153.41 and a 52-week-low of $32.00. Moreover, at the end of the last trading period, the closing price was at $54.42.

    For Air Products & Chemicals Inc (NYSE:APD), Wolfe Research downgraded the previous rating of Outperform to Peer Perform. In the fourth quarter, Air Products & Chemicals showed an EPS of $2.51, compared to $2.19 from the year-ago quarter. The current stock performance of Air Products & Chemicals shows a 52-week-high of $316.39 and a 52-week-low of $245.75. Moreover, at the end of the last trading period, the closing price was at $295.67.

    According to Morgan Stanley, the prior rating for Charter Communications Inc (NASDAQ:CHTR) was changed from Overweight to Equal-Weight. For the third quarter, Charter Communications had an EPS of $6.50, compared to year-ago quarter EPS of $3.90. At the moment, the stock has a 52-week-high of $825.62 and a 52-week-low of $585.45. Charter Communications closed at $642.07 at the end of the last trading period.

    According to Morgan Stanley, the prior rating for Allison Transmission Holdings Inc (NYSE:ALSN) was changed from Equal-Weight to Underweight. For the third quarter, Allison Transmission had an EPS of $0.89, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $46.40 and a 52-week-low of $32.55. At the end of the last trading period, Allison Transmission closed at $36.12.

    For Reata Pharmaceuticals Inc (NASDAQ:RETA), Baird downgraded the previous rating of Outperform to Neutral. For the third quarter, Reata Pharmaceuticals had an EPS of $1.27, compared to year-ago quarter EPS of $1.31. The stock has a 52-week-high of $153.41 and a 52-week-low of $32.00. At the end of the last trading period, Reata Pharmaceuticals closed at $54.42.

    For Zimmer Biomet Holdings Inc (NYSE:ZBH), Needham downgraded the previous rating of Strong Buy to Buy. Zimmer Biomet Holdings earned $1.81 in the third quarter, compared to $1.81 in the year-ago quarter. At the moment, the stock has a 52-week-high of $180.36 and a 52-week-low of $119.55. Zimmer Biomet Holdings closed at $128.96 at the end of the last trading period.

    JP Morgan downgraded the previous rating for Canadian Natural Resources Ltd (NYSE:CNQ) from Overweight to Neutral. Canadian Natural Res earned $1.41 in the third quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Canadian Natural Res shows a 52-week-high of $44.33 and a 52-week-low of $22.40. Moreover, at the end of the last trading period, the closing price was at $43.07.

    According to JP Morgan, the prior rating for Altice USA Inc (NYSE:ATUS) was changed from Overweight to Neutral. In the third quarter, Altice USA showed an EPS of $0.58, compared to $0.32 from the year-ago quarter. The current stock performance of Altice USA shows a 52-week-high of $38.30 and a 52-week-low of $15.47. Moreover, at the end of the last trading period, the closing price was at $15.86.

    According to JP Morgan, the prior rating for Enviva Partners LP (NYSE:EVA) was changed from Overweight to Neutral. Enviva Partners earned $0.63 in the third quarter, compared to $0.28 in the year-ago quarter. The current stock performance of Enviva Partners shows a 52-week-high of $73.33 and a 52-week-low of $44.01. Moreover, at the end of the last trading period, the closing price was at $72.95.

    JP Morgan downgraded the previous rating for SunPower Corp (NASDAQ:SPWR) from Neutral to Underweight. SunPower earned $0.06 in the third quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $57.52 and a 52-week-low of $19.75. SunPower closed at $24.94 at the end of the last trading period.

    According to RBC Capital, the prior rating for Cincinnati Financial Corp (NASDAQ:CINF) was changed from Outperform to Sector Perform. In the third quarter, Cincinnati Financial showed an EPS of $1.28, compared to $0.39 from the year-ago quarter. The current stock performance of Cincinnati Financial shows a 52-week-high of $127.25 and a 52-week-low of $78.56. Moreover, at the end of the last trading period, the closing price was at $117.21.

    According to RBC Capital, the prior rating for Marsh & McLennan Companies Inc (NYSE:MMC) was changed from Outperform to Sector Perform. In the third quarter, Marsh & McLennan showed an EPS of $1.08, compared to $0.82 from the year-ago quarter. At the moment, the stock has a 52-week-high of $174.90 and a 52-week-low of $106.95. Marsh & McLennan closed at $172.91 at the end of the last trading period.

    According to JP Morgan, the prior rating for CVR Energy Inc (NYSE:CVI) was changed from Neutral to Underweight. In the third quarter, CVR Energy showed an EPS of $0.24, compared to $0.57 from the year-ago quarter. The current stock performance of CVR Energy shows a 52-week-high of $27.02 and a 52-week-low of $11.22. Moreover, at the end of the last trading period, the closing price was at $16.50.

    According to Chardan Capital, the prior rating for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was changed from Buy to Neutral. Dicerna Pharmaceuticals earned $0.22 in the third quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Dicerna Pharmaceuticals shows a 52-week-high of $40.14 and a 52-week-low of $19.06. Moreover, at the end of the last trading period, the closing price was at $38.00.

    According to Wells Fargo, the prior rating for Allstate Corp (NYSE:ALL) was changed from Equal-Weight to Underweight. Allstate earned $0.73 in the third quarter, compared to $2.94 in the year-ago quarter. At the moment, the stock has a 52-week-high of $140.00 and a 52-week-low of $102.44. Allstate closed at $109.02 at the end of the last trading period.

    See all analyst ratings downgrades.

    Initiations

    With a Buy rating, EF Hutton initiated coverage on Trxade Health Inc (NASDAQ:MEDS). The price target seems to have been set at $4.50 for Trxade Health. In the third quarter, Trxade Health showed an EPS of $0.16, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $10.82 and a 52-week-low of $2.61. Trxade Health closed at $3.06 at the end of the last trading period.

    With a Buy rating, Alliance Global Partners initiated coverage on XORTX Therapeutics Inc (NASDAQ:XRTX). The price target seems to have been set at $11.00 for XORTX Therapeutics. XORTX Therapeutics earned $0.03 in the fourth quarter, compared to $0.24 in the year-ago quarter.

    Truist Securities initiated coverage on WR Berkley Corp (NYSE:WRB) with a Buy rating. The price target for WR Berkley is set to $105.00. For the third quarter, WR Berkley had an EPS of $1.32, compared to year-ago quarter EPS of $0.65. The current stock performance of WR Berkley shows a 52-week-high of $84.93 and a 52-week-low of $61.49. Moreover, at the end of the last trading period, the closing price was at $79.90.

    Wells Fargo initiated coverage on AbbVie Inc (NYSE:ABBV) with an Overweight rating. The price target for AbbVie is set to $165.00. For the third quarter, AbbVie had an EPS of $3.33, compared to year-ago quarter EPS of $2.83. The current stock performance of AbbVie shows a 52-week-high of $122.45 and a 52-week-low of $101.55. Moreover, at the end of the last trading period, the closing price was at $121.87.

    Wells Fargo initiated coverage on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with an Overweight rating. The price target for Regeneron Pharmaceuticals is set to $750.00. Regeneron Pharmaceuticals earned $15.37 in the third quarter, compared to $8.36 in the year-ago quarter. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $686.62 and a 52-week-low of $441.00. Moreover, at the end of the last trading period, the closing price was at $654.04.

    Wells Fargo initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:VRTX) with an Overweight rating. The price target for Vertex Pharmaceuticals is set to $270.00. In the third quarter, Vertex Pharmaceuticals showed an EPS of $3.56, compared to $2.64 from the year-ago quarter. The stock has a 52-week-high of $242.99 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $206.61.

    With an Overweight rating, Wells Fargo initiated coverage on Merck & Co Inc (NYSE:MRK). The price target seems to have been set at $90.00 for Merck & Co. For the third quarter, Merck & Co had an EPS of $1.75, compared to year-ago quarter EPS of $1.74. At the moment, the stock has a 52-week-high of $91.40 and a 52-week-low of $15.32. Merck & Co closed at $73.21 at the end of the last trading period.

    Wells Fargo initiated coverage on Biogen Inc (NASDAQ:BIIB) with a Equal-Weight rating. The price target for Biogen is set to $250.00. For the third quarter, Biogen had an EPS of $4.77, compared to year-ago quarter EPS of $8.84. The current stock performance of Biogen shows a 52-week-high of $468.55 and a 52-week-low of $221.72. Moreover, at the end of the last trading period, the closing price was at $234.72.

    Wells Fargo initiated coverage on Pfizer Inc (NYSE:PFE) with an Overweight rating. The price target for Pfizer is set to $60.00. Pfizer earned $1.34 in the third quarter, compared to $0.72 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.70 and a 52-week-low of $33.36. Pfizer closed at $51.40 at the end of the last trading period.

    With a Equal-Weight rating, Wells Fargo initiated coverage on Bristol-Myers Squibb Co (NYSE:BMY). The price target seems to have been set at $58.00 for Bristol-Myers Squibb. In the third quarter, Bristol-Myers Squibb showed an EPS of $2.00, compared to $1.63 from the year-ago quarter. The current stock performance of Bristol-Myers Squibb shows a 52-week-high of $69.75 and a 52-week-low of $53.22. Moreover, at the end of the last trading period, the closing price was at $57.60.

    Wells Fargo initiated coverage on Amgen Inc (NASDAQ:AMGN) with a Equal-Weight rating. The price target for Amgen is set to $210.00. In the third quarter, Amgen showed an EPS of $4.67, compared to $4.37 from the year-ago quarter. The current stock performance of Amgen shows a 52-week-high of $276.69 and a 52-week-low of $198.64. Moreover, at the end of the last trading period, the closing price was at $213.53.

    Wells Fargo initiated coverage on Gilead Sciences Inc (NASDAQ:GILD) with a Equal-Weight rating. The price target for Gilead Sciences is set to $72.00. In the third quarter, Gilead Sciences showed an EPS of $2.65, compared to $2.11 from the year-ago quarter. The current stock performance of Gilead Sciences shows a 52-week-high of $73.34 and a 52-week-low of $56.56. Moreover, at the end of the last trading period, the closing price was at $69.71.

    With a Equal-Weight rating, Wells Fargo initiated coverage on Eli Lilly and Co (NYSE:LLY). The price target seems to have been set at $270.00 for Eli Lilly. In the third quarter, Eli Lilly showed an EPS of $1.94, compared to $1.54 from the year-ago quarter. At the moment, the stock has a 52-week-high of $275.87 and a 52-week-low of $146.91. Eli Lilly closed at $244.32 at the end of the last trading period.

    Maxim Group initiated coverage on Recruiter.Com Group Inc (NASDAQ:RCRT) with a Buy rating. The price target for Recruiter.Com Group is set to $9.00. The current stock performance of Recruiter.Com Group shows a 52-week-high of $5.86 and a 52-week-low of $1.55. Moreover, at the end of the last trading period, the closing price was at $3.76.

    Macquarie initiated coverage on Informatica Inc (NYSE:INFA) with an Outperform rating. The price target for Informatica is set to $40.00. For the third quarter, Informatica had an EPS of $0.23, compared to year-ago quarter EPS of $0.16.

    William Blair initiated coverage on Lindblad Expeditions Holdings Inc (NASDAQ:LIND) with a Market Perform rating. In the third quarter, Lindblad Expeditions showed an EPS of $0.50, compared to $0.56 from the year-ago quarter. The stock has a 52-week-high of $21.91 and a 52-week-low of $11.31. At the end of the last trading period, Lindblad Expeditions closed at $16.35.

    Susquehanna initiated coverage on Forward Air Corp (NASDAQ:FWRD) with a Positive rating. The price target for Forward Air is set to $132.00. For the third quarter, Forward Air had an EPS of $1.14, compared to year-ago quarter EPS of $0.61. The stock has a 52-week-high of $112.55 and a 52-week-low of $70.93. At the end of the last trading period, Forward Air closed at $109.90.

    Susquehanna initiated coverage on Old Dominion Freight Line Inc (NASDAQ:ODFL) with a Neutral rating. The price target for Old Dominion Freight Line is set to $395.00. In the third quarter, Old Dominion Freight Line showed an EPS of $2.47, compared to $1.71 from the year-ago quarter. At the moment, the stock has a 52-week-high of $373.58 and a 52-week-low of $189.45. Old Dominion Freight Line closed at $356.81 at the end of the last trading period.

    Susquehanna initiated coverage on Saia Inc (NASDAQ:SAIA) with a Positive rating. The price target for Saia is set to $400.00. Saia earned $2.86 in the third quarter, compared to $1.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $365.50 and a 52-week-low of $171.16. Saia closed at $330.34 at the end of the last trading period.

    With a Positive rating, Susquehanna initiated coverage on TFI International Inc (NYSE:TFII). The price target seems to have been set at $132.00 for TFI International. At the moment, the stock has a 52-week-high of $120.50 and a 52-week-low of $50.10. TFI International closed at $109.12 at the end of the last trading period.

    With a Buy rating, Stifel initiated coverage on Janus International Group Inc (NYSE:JBI). The price target seems to have been set at $17.00 for Janus Intl Gr. For the third quarter, Janus Intl Gr had an EPS of $0.11, compared to year-ago quarter EPS of $0.35. The current stock performance of Janus Intl Gr shows a 52-week-high of $15.94 and a 52-week-low of $11.60. Moreover, at the end of the last trading period, the closing price was at $12.48.

    With a Equal-Weight rating, Morgan Stanley initiated coverage on Upstart Holdings Inc (NASDAQ:UPST). The price target seems to have been set at $200.00 for Upstart Holdings. The stock has a 52-week-high of $401.49 and a 52-week-low of $22.61. At the end of the last trading period, Upstart Holdings closed at $194.37.

    JP Morgan initiated coverage on RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating. The price target for RAPT Therapeutics is set to $61.00. RAPT Therapeutics earned $0.63 in the third quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $43.26 and a 52-week-low of $14.89. RAPT Therapeutics closed at $30.89 at the end of the last trading period.

    With an Overweight rating, JP Morgan initiated coverage on EVgo Inc (NASDAQ:EVGO). The price target seems to have been set at $20.00 for EVgo. At the moment, the stock has a 52-week-high of $19.59 and a 52-week-low of $7.17. EVgo closed at $12.17 at the end of the last trading period.

    Stifel initiated coverage on Apollo Endosurgery Inc (NASDAQ:APEN) with a Buy rating. The price target for Apollo Endosurgery is set to $12.00. In the third quarter, Apollo Endosurgery showed an EPS of $0.23, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $10.39 and a 52-week-low of $3.23. At the end of the last trading period, Apollo Endosurgery closed at $8.59.

    With a Buy rating, DZ Bank initiated coverage on Cloudflare Inc (NYSE:NET). The price target seems to have been set at $200.00 for Cloudflare. For the third quarter, Cloudflare had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $221.64 and a 52-week-low of $60.96. Cloudflare closed at $160.44 at the end of the last trading period.

    Needham initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC) with a Buy rating. The price target for Bicycle Therapeutics is set to $85.00. In the third quarter, Bicycle Therapeutics showed an EPS of $0.59, compared to $0.52 from the year-ago quarter. The stock has a 52-week-high of $62.08 and a 52-week-low of $17.95. At the end of the last trading period, Bicycle Therapeutics closed at $56.00.

    With an Overweight rating, JP Morgan initiated coverage on FuboTV Inc (NYSE:FUBO). The price target seems to have been set at $28.00 for FuboTV. For the third quarter, FuboTV had an EPS of $0.59, compared to year-ago quarter EPS of $1.65. The stock has a 52-week-high of $62.29 and a 52-week-low of $14.64. At the end of the last trading period, FuboTV closed at $19.77.

    With an Outperform rating, Oppenheimer initiated coverage on Green Plains Inc (NASDAQ:GPRE). The price target seems to have been set at $46.00 for Green Plains. Green Plains earned $1.18 in the third quarter, compared to $1.05 in the year-ago quarter. The current stock performance of Green Plains shows a 52-week-high of $44.27 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $38.36.

    Oppenheimer initiated coverage on Opiant Pharmaceuticals Inc (NASDAQ:OPNT) with an Outperform rating. The price target for Opiant Pharmaceuticals is set to $42.00. Opiant Pharmaceuticals earned $0.56 in the third quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $32.77 and a 52-week-low of $7.86. At the end of the last trading period, Opiant Pharmaceuticals closed at $32.20.

    Oppenheimer initiated coverage on Benson Hill Inc (NYSE:BHIL) with an Outperform rating. The price target for Benson Hill is set to $9.00. For the third quarter, Benson Hill had an EPS of $0.19, compared to year-ago quarter EPS of $0.11.

    See all analyst ratings initiations.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ALL
    $ALSN
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Southwest Airlines Company
    $LUV
    2/27/2026$66.00Hold → Buy
    TD Cowen
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Rio Tinto Plc
    $RIO
    2/24/2026Overweight → Equal Weight
    Barclays
    Rio Tinto Plc
    $RIO
    2/23/2026Buy → Neutral
    Goldman
    More analyst ratings

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

    KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the final analy

    2/27/26 10:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brookfield Renewable Completes Annual Filings

    BROOKFIELD, News, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Brookfield Renewable (NYSE:BEP, BEPC, TSX:BEP, BEPC)) announced today the filing of its 2025 annual reports, including audited financial statements for the year ended December 31, 2025, on Forms 20-F with the SEC on EDGAR as well as with Canadian securities regulatory authorities on SEDAR+. These documents are available at bep.brookfield.com (or for Brookfield Renewable Corporation, at bep.brookfield.com/bepc), on the SEC's website at www.sec.gov and on SEDAR+'s website at www.sedarplus.ca. Hard copies will be provided to unitholders and shareholders free of charge upon request. Brookfield Renewable Brookfield Renewable operates one of

    2/27/26 9:30:48 AM ET
    $BEP
    $BEPC
    Electric Utilities: Central
    Utilities

    Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

    – Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne. "Since this program began nine years ago, significant progr

    2/27/26 9:00:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Pres, EMEA Van Zuilen Wilfred converted options into 3,182 shares and covered exercise/tax liability with 828 shares, increasing direct ownership by 10% to 25,809 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/27/26 4:07:39 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Officer Phipps Chad F converted options into 2,626 shares and covered exercise/tax liability with 1,057 shares, increasing direct ownership by 3% to 63,706 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/27/26 4:06:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Group President, Asia Pacific Yi Sang converted options into 2,785 shares, increasing direct ownership by 14% to 22,837 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/27/26 4:05:58 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $39,381,432 worth of shares (553,654 units at $71.13) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/25/26 8:02:15 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Large owner Icahn Carl C bought $16,445,044 worth of shares (783,404 units at $20.99) (SEC Form 4)

    4 - CVR ENERGY INC (0001376139) (Issuer)

    2/24/26 5:26:10 PM ET
    $CVI
    Integrated oil Companies
    Energy

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $35,744,460 worth of shares (505,582 units at $70.70) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/20/26 7:34:24 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    $ABBV
    $ALL
    $ALSN
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    SEC Filings

    View All

    SEC Form DEF 14C filed by FuboTV Inc.

    DEF 14C - FuboTV Inc. (0001484769) (Filer)

    2/27/26 4:05:14 PM ET
    $FUBO
    Movies/Entertainment
    Consumer Discretionary

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/27/26 9:50:34 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Brookfield Renewable Corporation Brookfield Renewable Corporat

    6-K - Brookfield Renewable Corp (0001791863) (Filer)

    2/27/26 9:48:48 AM ET
    $BEPC
    Electric Utilities: Central
    Utilities

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Southwest Air upgraded by TD Cowen with a new price target

    TD Cowen upgraded Southwest Air from Hold to Buy and set a new price target of $66.00

    2/27/26 8:22:43 AM ET
    $LUV
    Air Freight/Delivery Services
    Consumer Discretionary

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Proficient Auto Logistics Appoints Rohit Lal to Board of Directors

    JACKSONVILLE, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Proficient Auto Logistics, Inc. (NASDAQ:PAL) today announced that the Board of Directors (the "Board") of Proficient Auto Logistics, Inc. (the "Company") appointed Rohit Lal ("Mr. Lal") to serve as a member of the Board. Mr. Lal currently serves as the Executive Vice President of IT Strategy for Saia, Inc (NASDAQ:SAIA) ("Saia"), where he leads IT teams to develop and deliver enterprise-wide solutions from applications to analytics. "Rohit brings significant experience in enterprise technology strategy and digital transformation," said Rick O'Dell, Proficient's Chief Executive Officer. "His expertise will enhance our Board as we continu

    2/26/26 4:30:00 PM ET
    $PAL
    $SAIA
    Transportation Services
    Consumer Discretionary
    Trucking Freight/Courier Services
    Industrials

    CHARTER COMMUNICATIONS NAMES FRONTIER CEO NICK JEFFERY CHIEF OPERATING OFFICER

    STAMFORD, Conn., Feb. 25, 2026 /PRNewswire/ -- Charter Communications, Inc. (NASDAQ:CHTR) today announced the appointment of Nick Jeffery as its Chief Operating Officer. Jeffery will lead Marketing and Sales, Field Operations, and Customer Operations across Spectrum's residential and business Seamless Connectivity and Entertainment services. Based in Stamford, Jeffery will begin on September 1, 2026. In his new role as Chief Operating Officer, Jeffery will work closely as part of Charter's senior leadership team to build on the Company's assets, enhance its service reputation an

    2/25/26 8:30:00 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVR Energy Inc.

    SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

    1/7/25 6:12:47 AM ET
    $CVI
    Integrated oil Companies
    Energy

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Green Plains Inc.

    SC 13G - Green Plains Inc. (0001309402) (Subject)

    11/20/24 1:25:23 PM ET
    $GPRE
    Major Chemicals
    Industrials

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Financials

    Live finance-specific insights

    View All

    Allison Announces a 7 Percent Increase to the Quarterly Dividend and the Annual Stockholders Meeting and Record Date

    INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Allison Transmission Holdings Inc. (NYSE: ALSN), a global leader in high-performance mobility and work solutions built for the needs of the modern industrial world, announced today that its Board of Directors has approved an increase in the Company's quarterly dividend from $0.27 to $0.29 per share on the Company's common stock and has declared a cash dividend of $0.29 per share on the Company's common stock for the first quarter of 2026. Payment will be made on March 20, to stockholders of record at the close of business on March 9."For the seventh consecutive year, Allison's Board of Directors has approved an increase to the quarterly dividend, d

    2/26/26 4:05:00 PM ET
    $ALSN
    Auto Parts:O.E.M.
    Consumer Discretionary

    /C O R R E C T I O N -- Lindblad Expeditions Holdings, Inc./

    In the news release, Lindblad Expeditions Holdings, Inc. Reports 2025 Fourth Quarter and Full Year Financial Results, issued 26-Feb-2026 by Lindblad Expeditions Holdings, Inc. over PR Newswire, we are advised by the company that the conference call time is 9:00 a.m. Eastern Time on February 26, 2026 rather than 8:30 a.m. Eastern Time. The complete, corrected release follows: Lindblad Expeditions Holdings, Inc. Reports 2025 Fourth Quarter and Full Year Financial Results 2025 Delivered the Strongest Adjusted EBITDA Performance in Company HistoryHighlights:Total revenues increased 20% to $771.0 millionNet loss available to stockholders decreased $1.2 million to $34.6 million; including a $23.5

    2/26/26 7:30:00 AM ET
    $LIND
    Transportation Services
    Consumer Discretionary

    Lindblad Expeditions Holdings, Inc. Reports 2025 Fourth Quarter and Full Year Financial Results

    2025 Delivered the Strongest Adjusted EBITDA Performance in Company HistoryHighlights:Total revenues increased 20% to $771.0 millionNet loss available to stockholders decreased $1.2 million to $34.6 million; including a $23.5 million loss on extinguishment of debtAdjusted EBITDA increased 38% to $126.2 millionNet Yield per Available Guest Night increased 14% to $1,335 and Occupancy was 88%Refinanced long-term debt with $675.0 million of 7.00% senior secured notes, extending debt maturity to 2030, and increased the amount available under our revolving credit facility to $60.0 millionOn February 3, 2026, all outstanding Preferred Stock was converted into 9.0 million shares of Common StockNEW Y

    2/26/26 7:30:00 AM ET
    $LIND
    Transportation Services
    Consumer Discretionary